Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.radonc.2020.06.042 | DOI Listing |
Crit Rev Oncol Hematol
January 2025
Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. Electronic address:
There is a much debate regarding optimal selection in patients with metastatic cancer who should undergo local treatment (surgery or radiation treatment) to the primary tumor and/or metastases. Additionally, the optimal treatment of newly diagnosed metastatic cancer is largely unclear. Current prognostication systems to best inform these clinical scenarios are limited, as all metastatic patients are grouped together as having Stage IV disease without further incorporation of patient and disease-specific covariates that significantly impact patient outcomes.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Radiotherapy, Research Centre for Digital Medicine, VUB-UZ Brussel, 1090 Brussels, Belgium.
: Inadequate dosing and respiratory motion contribute to local recurrence for oligometastatic disease (OMD). While short-term LC rates are well-documented, data on long-term LC remain limited. This study investigated long-term LC after stereotactic body radiotherapy (SBRT), using respiratory motion management techniques.
View Article and Find Full Text PDFClin Exp Metastasis
January 2025
Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Purpose: Patients with nasopharyngeal carcinoma (NPC) experiencing locoregional recurrence concomitant with distant metastases (rmNPC) after initial treatment represent a unique subgroup with significant management challenges. This study aimed to evaluate overall survival (OS) in rmNPC patients treated with systemic therapies with or without radiotherapy.
Methods: This retrospective multicenter study included patients with locally recurrent and metastatic NPC from five hospitals.
Radiother Oncol
January 2025
GORTEC 4 bis rue Emile Zola 37000 Tours, France; Department of Radiotherapy, Centre François-Baclesse, Corpuscular Physics Laboratory, IN2P3, ENSICAEN, CNRS UMR 6534, Université de Normandie, Caen, France. Electronic address:
Purpose: The randomized phase II GORTEC 2014-04 and French Head and Neck Intergroup study showed deeper deterioration of the quality of life (HRQoL) and dramatically higher severe toxicity rates with similar overall survival rates using chemo-SABR compared to SABR alone in oligometastatic head and neck cancer (HNSCC) patients. We evaluated the costs associated with SABR-alone versus chemo-SABR and their associated costs (transportation, hospitalizations, etc).
Materials And Methods: 69 HNSCC patients with 1-3 oligometastases and a controlled primary were randomized from September 2015 to October 2022.
Global Spine J
January 2025
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Study Design: Narrative review of existing literature.
Objectives: Significant technological advancements in radiotherapy planning and delivery have enabled new radiotherapy techniques for the management of spine tumors. The objective of this study was to provide a comprehensive summary of these treatment techniques for practicing spine surgeons.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!